Delving into the Latest Updates on CSL Behring (Australia) Pty Ltd. with Synapse

概览

疾病领域	数量

血液及淋巴系统疾病	1
感染	1

排名前五的药物类型	数量

免疫球蛋白	1
腺相关病毒基因治疗	1

排名前五的靶点	数量

Tetanus toxin(破伤风毒素)	1
factor IX(凝血因子IX)	1

关联

2

项与 CSL Behring (Australia) Pty Ltd. 相关的药物

Etranacogene dezaparvovec

靶点

factor IX

作用机制

factor IX刺激剂

在研机构

CSL Behring LLC [+4]

原研机构

CSL Behring LLC

在研适应症

血友病B

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2022-11-22

Human anti-tetanus immunoglobulin(CSL Behring LLC)

靶点

Tetanus toxin

作用机制

破伤风毒素抑制剂

在研机构

CSL Behring (Australia) Pty Ltd. [+1]

原研机构

CSL Behring LLC

在研适应症

破伤风

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

澳大利亚

首次获批日期1991-11-04

100 项与 CSL Behring (Australia) Pty Ltd. 相关的临床结果

登录后查看更多信息

0 项与 CSL Behring (Australia) Pty Ltd. 相关的专利（医药）

登录后查看更多信息

3

项与 CSL Behring (Australia) Pty Ltd. 相关的文献（医药）

2017-09-03·Journal of Immunoassay and Immunochemistry

Improvement of ELISA procedures through simultaneous addition of antigen and detection antibody and elimination of washing steps

Article

作者: Bertolini, J. ; Gurevich, V. ; McCann, K. ; Kotharu, P.

The enzyme-linked immunosorbent assay (ELISA) is extensively used for measurement of proteins utilized for various research and diagnostic purposes in the biological disciplines. However, it is a labor-intensive and lengthy procedure due to a number of incubation and washing steps required for performing the assay. The ELISA procedure in the current study has been simplified through the simultaneous addition of antigen and detection antibody and elimination of washing steps. This resulted in a decreased time required to perform the procedure and without affecting assay capability. This approach offers the possibility of increasing ELISA productivity in low throughput laboratories without the need for alternative analytical platforms which would require significant assay redevelopment and capital expense.

2017-08-03·Human Vaccines & Immunotherapeutics3区 · 医学

Rubella antibodies in Australian immunoglobulin products

3区 · 医学

Article

作者: Bertolini, Joseph ; Young, Megan K. ; Kotharu, Pushpa ; Maher, Darryl ; Cripps, Allan W.

Rubella antibodies are not routinely measured in immunoglobulin products and there is a lack of information on the titer in Australian products. To facilitate future studies of the effectiveness of passive immunisation for preventing rubella and congenital rubella syndrome, this study measured the concentration of rubella-specific antibodies in Australian intramuscular (IM) and intravenous (IV) human immunoglobulin products suitable for post-exposure prophylaxis using a chemiluminescent immunoassay. The GMT ± GSD for the IM product was 19 ± 1.2 IU/mg (2980 ± 1.2 IU/mL). The GMT ± GSD for the IV product was 12 ± 1.5 IU/mg (729 ± 1.5 IU/mL). At present, Australian guidelines recommend offering non-immune pregnant women exposed to rubella 20 mL of intramuscular immunoglobulin within 72 hours of exposure. This equates to 42,160 IU of rubella antibodies if the lowest titer obtained for the Australian IM product is considered. The same dose would be delivered by 176 mL of the Australian IV product at the lowest measured rubella-specific antibody titer.

2017-03-04·Human Vaccines & Immunotherapeutics3区 · 医学

Do Australian immunoglobulin products meet international measles antibody titer standards?

3区 · 医学

Article

作者: Bertolini, Joseph ; Young, Megan K. ; Kotharu, Pushpa ; Maher, Darryl ; Cripps, Allan W.

The effectiveness of passive immunisation post-exposure to measles appears subject to a dose-response effect. New Zealand and the United Kingdom have increased the recommended dose of polyclonal human immunoglobulin for post-exposure prophylaxis within the last decade in response to concerns about decreasing levels of measles antibodies in these products. This study used the plaque-reduction neutralization test (PRNT) to measure the titer of measles-specific antibodies in Australian immunoglobulin products for post-exposure prophylaxis and compared the utility of an enzyme-linked immunosorbent assay (ELISA) to the PRNT in available Australian and international samples: Australian intramuscular (n = 10), Australian intravenous (n = 28), New Zealand intramuscular (n = 2), Hizentra (subcutaneous)(USA) (n = 3), and Privigen (intravenous)(USA) (n = 2). Measles titres in Australian IM and IV immunoglobulins ranged from 51 to 76 IU/mL and 6 to 24 IU/mL respectively, as measured by PRNT calibrated to the WHO 3^rd international standard. ELISA titres were variable but higher than PRNT titres in all tested samples. Measles antibody titres in Australian immunoglobulin products meet consensus-prescribed international thresholds. Development of a convenient, standardized, readily accessible assay for determination of measles titres in immunoglobulin products would be useful for future studies and facilitate international comparisons.

100 项与 CSL Behring (Australia) Pty Ltd. 相关的药物交易

登录后查看更多信息

100 项与 CSL Behring (Australia) Pty Ltd. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月05日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

批准上市

2

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Etranacogene dezaparvovec ( factor IX )	血友病B 更多	批准上市
Human anti-tetanus immunoglobulin(CSL Behring LLC) ( Tetanus toxin )	破伤风更多	批准上市